When probing for tumor cell proliferation via Ki67 expression in the endpoint tumors, we found that all treatment groups exhibited relatively low levels of Ki67, except for the single-agent Trametinib-treated group, which displayed increased Ki67 staining despite the increased survival time compared to the vehicle and Omipalisib-treated groups (Figure 5E). Here, MKI67 is linked to neoplasm.